36 Degradation of type III and IV collagen associates with outcome when measured in serum from patients with metastatic melanoma treated with immune checkpoint inhibitors

Ítems similars

• 36 Degradation of type III and IV collagen associates with outcome when measured in serum from patients with metastatic melanoma treated with immune checkpoint inhibitors
  per: Marco Donia, et al.
  Publicat: (2023-11-01)
• Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
  per: Jan-Michael Werner, et al.
  Publicat: (2019-02-01)
• Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy
  per: Christina Jensen, et al.
  Publicat: (2021-10-01)
• Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy
  per: Chad Pickering, et al.
  Publicat: (2023-06-01)
• Preliminary investigation of elevated collagen and blood‐clotting markers as potential noninvasive biomarkers for small cell lung cancer
  per: Jeppe Thorlacius‐Ussing, et al.
  Publicat: (2023-10-01)